Jefferies Maintains Buy Rating on Ariad Pharma

According to Jefferies, Ariad Pharma

Buy rating is maintained. Jefferies said that in ASH oral presentation for ponatinib Ph2 study (

), interim numerical efficacy data is similar to that in abstract (but in a larger # of pts). “At median 5.6-month FU, overall CP-CML MCyR was ~47% (vs. 46% previously); non-T315i/T315i mutation MCyR was 41%/65%, with improved T315iM response vs. previously. Additional details at ARIA Investor Breakfast on Dec. 12.” Ariad Pharma closed on Friday at $13.60.